E. Marangoni

Ants act as olfactory bio-detectors of tumour in patient-derived xenograft mice

This study shows ants can be trained to detect tumour-specific VOCs in mice urine, indicating their potential as cancer bio-detectors.

Nuclear NAD+ homeostasis is essential for naive and chemoresistant BRCA1/2-deficient tumor survival

This study identifies NMNAT1 as a therapeutic target for BRCA1/2-deficient tumors, showing its synthetic lethality with BRCA1/2 in a PARP1-independent but SIRT6-dependent manner.

A Network Approach to Identify Biomarkers of Differential Chemotherapy Response Using Patient-Derived Xenografts of Triple-Negative Breast Cancer

This paper identifies biomarkers of differential chemotherapy response in TNBC using a network-based approach and validates them in PDX models and clinical datasets.

Modeling breast cancer by grafting patient tumor samples in the avian embryo: an in vivo platform for therapy evaluation coupled to large scale molecular analyses

The paper develops an in vivo model using avian embryos to study triple negative breast cancer and evaluate therapies through molecular analysis.

mTOR repression in response to amino acid starvation promotes ECM degradation through MT1-MMP endocytosis arrest

The paper shows that mTOR repression during amino acid starvation leads to increased ECM degradation via MT1-MMP endocytosis arrest in tumor cells.

H3K27me3 is a determinant of chemotolerance in triple-negative breast cancer

This study identifies H3K27me3 as a key determinant of chemotolerance in triple-negative breast cancer by analyzing single-cell epigenomic and transcriptomic data.

YAP and β-catenin co-operate to drive oncogenesis in basal breast cancer

This study shows YAP and β-catenin cooperate in basal breast cancer to drive CSCs, with targeting this complex as a potential therapeutic strategy.

GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers

This study identifies GATA3 and MDM2 as synthetic lethal in ER-positive breast cancers, showing MDM2 inhibition can target GATA3-deficient tumors via the PI3K/Akt/mTOR pathway.

Targeting STAT3 signalling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer

This study shows that SFX-01 reduces CSC activity in ER+ breast cancer by inhibiting STAT3 signaling, improving outcomes in endocrine-resistant models.

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

This study shows that copy number profiles are conserved in patient-derived xenografts (PDXs) through engraftment and passaging, indicating minimal impact from the mouse host on tumor evolution.

Coordinate Enhancer Reprogramming by GATA3 and AP1 Promotes Phenotypic Plasticity to Achieve Breast Cancer Endocrine Resistance

This study identifies GATA3 and AP1-driven enhancer reprogramming as a mechanism promoting phenotypic plasticity and endocrine resistance in breast cancer.